MoonLake Immunotherapeutics - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of MoonLake Immunotherapeutics Company

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

MoonLake Immunotherapeutics Info



Ticker SymbolMLTX

Company nameMoonLake Immunotherapeutics

IPO dateOct 20, 2020

CEODr. Jorge Santos Da Silva

Number of employees100

Security typeOrdinary Share

Fiscal year-endOct 20

AddressDorfstrasse 29

CityZUG

Stock exchangeNASDAQ Capital Market Consolidated

CountrySwitzerland

Postal code6300

Phone41415108022

Websitehttps://moonlaketx.com/

Ticker SymbolMLTX

IPO dateOct 20, 2020

CEODr. Jorge Santos Da Silva

Company Executives of MoonLake Immunotherapeutics



Name

Name/Position

Position

Shareholding

Change

Dr. Kristian Reich

Chief Scientific Officer

3.13M

+1.59%

Dr. Jorge Santos Da Silva

Chief Executive Officer, Director

3.08M

--

Mr. Matthias Bodenstedt

Chief Financial Officer

627.54K

+1.76%

Mr. Simon Sturge

Independent Chairman of the Board

171.98K

--

Dr. Andrew J. Phillips

Independent Director

--

Dr. Atif Khan

Director - Strategic Planning and Projects

--

Ms. Catherine Moukheibir

Independent Director

--

Dr. Ramnik Xavier

Independent Director

--

Mr. Spike N. Loy, J.D.

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. Kristian Reich

Chief Scientific Officer

3.13M

+1.59%

Dr. Jorge Santos Da Silva

Chief Executive Officer, Director

3.08M

--

Mr. Matthias Bodenstedt

Chief Financial Officer

627.54K

+1.76%

Mr. Simon Sturge

Independent Chairman of the Board

171.98K

--

Dr. Andrew J. Phillips

Independent Director

--

Dr. Atif Khan

Director - Strategic Planning and Projects

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Tue, Nov 4

Shareholders

Shareholder Types

Shareholders

Proportion

BVF Partners L.P.

27.67%

Fidelity Management & Research Company LLC

7.44%

Avoro Capital Advisors LLC

5.81%

Reich (Kristian)

4.38%

Santos da Silva (Jorge)

4.31%

Other

50.37%

Shareholders

Proportion

BVF Partners L.P.

27.67%

Fidelity Management & Research Company LLC

7.44%

Avoro Capital Advisors LLC

5.81%

Reich (Kristian)

4.38%

Santos da Silva (Jorge)

4.31%

Other

50.37%

Shareholder Types

Shareholders

Proportion

Hedge Fund

41.51%

Investment Advisor

20.11%

Investment Advisor/Hedge Fund

17.19%

Individual Investor

11.03%

Research Firm

2.11%

Venture Capital

1.30%

Bank and Trust

0.07%

Pension Fund

0.05%

Other

6.62%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

336

52.26M

73.22%

-13.87M

2025Q2

326

71.15M

112.06%

-8.45M

2025Q1

329

71.47M

112.59%

-8.98M

2024Q4

308

74.57M

117.86%

+1.09M

2024Q3

292

73.42M

116.42%

+551.38K

2024Q2

282

72.21M

114.78%

+1.82M

2024Q1

274

70.82M

112.58%

-306.27K

2023Q4

260

64.82M

107.09%

-2.17M

2023Q3

219

60.33M

114.64%

-5.55M

2023Q2

175

60.28M

100.54%

+9.44M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

BVF Partners L.P.

19.75M

31.1%

--

Jun 30, 2025

Fidelity Management & Research Company LLC

5.31M

8.36%

-114.00K

-2.10%

Jun 30, 2025

Avoro Capital Advisors LLC

4.15M

6.54%

+1.38M

+49.81%

Jun 30, 2025

Reich (Kristian)

3.13M

4.93%

+48.98K

+1.59%

Sep 02, 2025

Santos da Silva (Jorge)

3.08M

4.85%

--

Mar 15, 2025

T. Rowe Price Associates, Inc.

2.61M

4.12%

-360.60K

-12.13%

Jun 30, 2025

Cormorant Asset Management, LP

1.99M

3.14%

-6.50M

-76.52%

Sep 30, 2025

Citadel Advisors LLC

1.67M

2.64%

+195.41K

+13.22%

Jun 30, 2025

Westfield Capital Management Company, L.P.

1.26M

1.98%

-175.39K

-12.22%

Jun 30, 2025

Goldman Sachs & Company, Inc.

1.26M

1.98%

-19.32K

-1.52%

Jun 30, 2025

Related ETFs



Updated: Thu, Nov 6

Name

Proportion

ALPS Medical Breakthroughs ETF

0.27%

Global X Guru Index ETF

0.16%

Goldman Sachs Future Health Care Equity ETF

0.12%

Virtus LifeSci Biotech Clinical Trials ETF

0.12%

JPMorgan Healthcare Leaders ETF

0.03%

First Trust IPOX Europe Equity Opportunities ETF

0.02%

JPMorgan BetaBuilders US Small Cap Equity ETF

0.01%

John Hancock Multifactor Small Cap ETF

0.01%

iShares ESG Aware MSCI USA Small-Cap ETF

0.01%

Fidelity Blue Chip Growth ETF

0.01%

ALPS Medical Breakthroughs ETF

Proportion0.27%

Global X Guru Index ETF

Proportion0.16%

Goldman Sachs Future Health Care Equity ETF

Proportion0.12%

Virtus LifeSci Biotech Clinical Trials ETF

Proportion0.12%

JPMorgan Healthcare Leaders ETF

Proportion0.03%

First Trust IPOX Europe Equity Opportunities ETF

Proportion0.02%

JPMorgan BetaBuilders US Small Cap Equity ETF

Proportion0.01%

John Hancock Multifactor Small Cap ETF

Proportion0.01%

iShares ESG Aware MSCI USA Small-Cap ETF

Proportion0.01%

Fidelity Blue Chip Growth ETF

Proportion0.01%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data